Prostaglandin endoperoxide H synthase inhibitors and other tocolytics in preterm labour

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 70, Issue 2, 2004, Pages 167-187

  Mitchell, Bryan F ^a   Olson, David M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

COX 1; COX 2; Cyclooxygenase; Fetus; Preterm birth; Prostaglandin; Prostaglandin endoperoxide H synthase; Tocolytics

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ATOSIBAN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; HEXOPRENALINE; INDOMETACIN; ISOXSUPRINE; MAGNESIUM SULFATE; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; OXYTOCIN ANTAGONIST; PROSTAGLANDIN SYNTHASE INHIBITOR; RITODRINE; ROFECOXIB; SALBUTAMOL; TERBUTALINE; UTERUS SPASMOLYTIC AGENT;

ALCOHOL INTOXICATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEVELOPED COUNTRY; FLUID RETENTION; GESTATIONAL AGE; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; KIDNEY FAILURE; LIFESTYLE; LUNG EDEMA; METABOLIC DISORDER; NEWBORN DEATH; NONHUMAN; OBSTETRIC CARE; OLIGOHYDRAMNIOS; PREMATURE LABOR; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS SYNDROME; REVIEW; SIDE EFFECT; ULCER; UTERUS CONTRACTILITY; X RAY CRYSTALLOGRAPHY;

EID: 0942301250     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2003.04.006     Document Type: Article

References (210)

1. G.S. Berkowitz, E. Papiernik, Epidemiology of preterm birth, Epidemiol. Rev. 15 (1993) 414-443.
2. K.S. Joseph, M.S. Kramer, S. Marcoux, et al., Determinants of preterm birth rates in Canada from 1981 through 1983 and from 1992 through 1994, N. Engl. J. Med. 339 (1998) 1434-1439.
3. T. Arbuckle, S. Dzakpasu, S. Liu, et al., Canadian Perinatal Health Report, Canadian Perinatal Surveillance System, 2000, pp. 53-55.
4. J. Magill-Evans, M.J. Harrison, J. Van der Zalm, G. Holdgrafer, Cognitive and language development of healthy preterm infants at 10 years of age, Phys. Occup. Ther. Pediatr. 22 (2002) 41-56.
5. J.M. Moutquin, E. Papiernik, Can we lower the rate of preterm birth? Bulletin of the Society of Obstetricians and Gynecologits of Canada, 1990, pp. 19-20.
6. D.M. Olson, J.E. Mijovic, D.W. Sadowsky, Control of human parturition, Semin. Perinatol. 19 (1995) 52-63.
7. J.R. Challis, S.J. Lye, Parturition, in: E.N.J. Knobil (Ed.), The Physiology of Reproduction, Raven Press, New York, 1994, pp. 985-1031.
8. W.L. Xie, J.G. Chipman, D.L. Robertson, R.L. Erikson, D.L. Simmons, Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing, Proc. Natl. Acad. Sci. USA 88 (1991) 2692-2696.
9. J.C. Otto, W.L. Smith, Photolabeling of prostaglandin endoperoxide H synthase-1 with 3-trifluoro-3-(m-[125I]iodophenyl)diazirine as a probe of membrane association and the cyclooxygenase active site, J. Biol. Chem. 271 (1996) 9906-9910.
10. A.G. Spencer, E. Thuresson, J.C. Otto, et al., The membrane binding domains of prostaglandin endoperoxide H synthases 1 and 2. Peptide mapping and mutational analysis, J. Biol. Chem. 274 (1999) 32936-32942.
11. D.L. DeWitt, E.A. Meade, W.L. Smith, PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs, Am. J. Med. 95 (1993) 40S-44S.
12. M.D. Percival, M. Ouellet, C.J. Vincent, J.A. Yergey, B.P. Kennedy, G.P. O'Neill, Purification and characterization of recombinant human cyclooxygenase-2, Arch. Biochem. Biophys. 315 (1994) 111-118.
13. J.R. Vane, Y.S. Bakhle, R.M. Botting, Cyclooxygenases 1 and 2, Annu. Rev. Pharmacol. Toxicol. 38 (1998) 97-120.
14. W.L. Smith, D.L. DeWitt, R.M. Garavito, Cyclooxygenases: structural, cellular, and molecular biology, Annu. Rev. Biochem. 69 (2000) 145-182.
15. C. Luong, A. Miller, J. Barnett, J. Chow, C. Ramesha, M.F. Browner, Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2, Nat. Struct. Biol. 3 (1996) 927-933.
16. R.G. Kurumbail, A.M. Stevens, J.K. Gierse, et al., Structural basis for selective inhibition of cyclooxygenase-2 by antiinflammatory agents, Nature 384 (1996) 644-648.
17. W.L. Smith, R.M. Garavito, D.L. DeWitt, Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2, J. Biol. Chem. 271 (1996) 33157-33160.
18. H.R. Herschman, Prostaglandin synthase 2, Biochim. Biophys. Acta 1299 (1996) 125-140.
19. I. Morita, M. Schindler, M.K. Regier, et al., Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2, J. Biol. Chem. 270 (1995) 10902-10908.
20. D.C. Swinney, A.Y. Mak, J. Barnett, C.S. Ramesha, Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid, J. Biol. Chem. 272 (1997) 12393-12398.
21. N.V. Chandrasekharan, H. Dai, K.L. Roos, et al., COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression, Proc. Natl. Acad. Sci. USA 99 (2002) 13926-13931.
22. R.M. Botting, Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin. Infect. Dis. 31 (Suppl. 5) (2000) S202-S210.
23. T.D. Warner, J.A. Mitchell, Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc. Natl. Acad. Sci. USA 99 (2002) 13371-13373.
24. J.R. Challis, D.M. Olson, Parturition, in: E. Knobil, J. Neill (Eds.), The Physiology of Reproduction, Raven Press, New York, 1988, pp. 2177-2216.
25. D.J. Crankshaw, R. Dyal, Effects of some naturally occurring prostanoids and some cyclooxygenase inhibitors on the contractility of the human lower uterine segment in vitro, Can. J. Physiol. Pharmacol. 72 (1994) 870-874.
26. J. Senior, K. Marshall, R. Sangha, G.S. Baxter, J.K. Clayton, In vitro characterization of prostanoid EP-receptors in the non-pregnant human myometrium, Br. J. Pharmacol. 102 (1991) 747-753.
27. J. Senior, K. Marshall, R. Sangha, J.K. Clayton, In vitro characterization of prostanoid receptors on human myometrium at term pregnancy, Br. J. Pharmacol. 108 (1993) 501-506.
28. J. Senior, R. Sangha, G.S. Baxter, K. Marshall, J.K. Clayton, In vitro characterization of prostanoid FP-, DP-, IP-and TP-receptors on the non-pregnant human myometrium, Br. J. Pharmacol. 107 (1992) 215-221.
29. J.J. Hirst, J.E. Mijovic, T. Zakar, D.M. Olson, Prostaglandin endoperoxide H synthase-1 and -2 mRNA levels and enzyme activity in human decidua at term labor, J. Soc. Gynecol. Invest. 5 (1998) 13-20.
30. J.J. Hirst, F.J. Teixeira, T. Zakar, D.M. Olson, Prostaglandin endoperoxide-H synthase-1 and -2 messenger ribonucleic acid levels in human amnion with spontaneous labor onset, J. Clin. Endocrinol. Metab. 80 (1995) 517-523.
31. J.J. Hirst, F.J. Teixeira, T. Zakar, D.M. Olson, Prostaglandin H synthase-2 expression increases in human gestational tissues with spontaneous labour onset, Reprod. Fertil. Dev. 7 (1995) 633-637.
32. J.E. Mijovic, T. Zakar, J. Angelova, D.M. Olson, Prostaglandin endoperoxide H synthase mRNA expression in the human amnion and decidua during pregnancy and in the amnion at preterm labour, Mol. Hum. Reprod. 5 (1999) 182-187.
33. J.E. Mijovic, T. Zakar, T.K. Nairn, D.M. Olson, Prostaglandin endoperoxide H synthase (PGHS) activity and PGHS-1 and -2 messenger ribonucleic acid abundance in human chorion throughout gestation and with preterm labor, J. Clin. Endocrinol. Metab. 83 (1998) 1358-1367.
34. J.E. Mijovic, T. Zakar, T.K. Nairn, D.M. Olson, Prostaglandin- endoperoxide H synthase-2 expression and activity increases with term labor in human chorion, Am. J. Physiol. 272 (1997) E832-840.
35. J.E. Mijovic, T. Zakar, D.M. Olson, Prostaglandin endoperoxidase H synthase (PGHS)-1 and -2 expression and activity in human chorion and decidua, Trophoblast Res. 11 (1998) 209-228.
36. D. Slater, V. Allport, P. Bennett, Changes in the expression of the type-2 but not the type-1 cyclooxygenase enzyme in choriondecidua with the onset of labour, Br. J. Obstet. Gynaecol. 105 (1998) 745-748.
37. D. Slater, W. Dennes, R. Sawdy, V. Allport, P. Bennett, Expression of cyclooxygenase types-1 and -2 in human fetal membranes throughout pregnancy, J. Mol. Endocrinol. 22 (1999) 125-130.
38. M. Doret, G. Mellier, M. Benchaib, J.M. Piacenza, C. Gharib, J.C. Pasquier, In vitro study of tocolytic effect of rofecoxib, a specific cyclooxygenase 2 inhibitor. Comparison and combination with other tocolytic agents, Bjog 109 (2002) 983-988.
39. M.H. Yousif, O. Thulesius, Tocolytic effect of the cyclooxygenase-2 inhibitor, meloxicam: studies on uterine contractions in the rat, J. Pharm. Pharmacol. 50 (1998) 681-685.
40. Y. Sadovsky, D.M. Nelson, L.J. Muglia, et al., Effective diminution of amniotic prostaglandin production by selective inhibitors of cyclooxygenase type 2, Am. J. Obstet. Gynecol. 182 (2000) 370-376.
41. P.L. Grigsby, K.R. Poore, J.J. Hirst, G. Jenkin, Inhibition of premature labor in sheep by a combined treatment of nimesulide, a prostaglandin synthase type 2 inhibitor, and atosiban, an oxytocin receptor antagonist, Am. J. Obstet. Gynecol. 183 (2000) 649-657.
42. K.R. Poore, I.R. Young, J.J. Hirst, Efficacy of the selective prostaglandin synthase type 2 inhibitor nimesulide in blocking basal prostaglandin production and delaying glucocorticoid-induced premature labor in sheep, Am. J. Obstet. Gynecol. 180 (1999) 1244-1253.
43. K.J. McKeown, J.R. Challis, C. Small, et al., Altered fetal pituitary-adrenal function in the ovine fetus treated with RU486 and meloxicam, an inhibitor of prostaglandin synthase-II, Biol. Reprod. 63 (2000) 1899-1904.
44. M. Sakai, K. Tanebe, Y. Sasaki, K. Momma, S. Yoneda, S. Saito, Evaluation of the tocolytic effect of a selective cyclooxygenase-2 inhibitor in a mouse model of lipopolysaccharide-induced preterm delivery, Mol. Hum. Reprod. 7 (2001) 595-602.
45. M.S. Reece, J.A. McGregor, K.G. Allen, M.M. Mathias, M.A. Harris, Prostaglandins in selected reproductive tissues in preterm and full-term gestations, Prostagl. Leukot. Essent. Fatty Acids 55 (1996) 303-307.
46. F.J. Teixeira, T. Zakar, J.J. Hirst, et al., Prostaglandin endoperoxide H synthase (PGHS) activity and immunoreactive PGHS-1 and -2 levels in human amnion throughout gestation and at labor, J. Clin. Endocrinol. Metab. 79 (1994) 1396-1402.
47. E.P. Spaziani, J.C. Tsibris, L.T. Hunt, R.R. Benoit, W.F. O'Brien, The effect of interleukin-1 beta and interleukin-4 on the expression of prostaglandin receptors EP1 and EP3 in amnion WISH cells, Am. J. Reprod. Immunol. 38 (1997) 279-285.
48. E.P. Spaziani, W.F. O'Brien, J.C. Tsibris, R.R. Benoit, S.F. Gould, Modulation of the prostaglandin E receptor: a possible mechanism for infection-induced preterm labor, Obstet. Gynecol. 93 (1999) 84-88.
49. J.A. McCoshen, K.A. Johnson, N.H. Dubin, R.B. Ghodgaonkar, Prostaglandin E2 release on the fetal and maternal sides of the amnion and chorion-decidua before and after term labor, Am. J. Obstet. Gynecol. 156 (1987) 173-178.
50. J.A. McCoshen, D.R. Hoffman, J.V. Kredentser, C. Araneda, J.M. Johnston, The role of fetal membranes in regulating production, transport, and metabolism of prostaglandin E2 during labor, Am. J. Obstet. Gynecol. 163 (1990) 1632-1640.
51. B.F. Mitchell, K. Rogers, S. Wong, The dynamics of prostaglandin metabolism in human fetal membranes and decidua around the time of parturition, J. Clin. Endocrinol. Metab. 77 (1993) 759-764.
52. J. McLaren, D.J. Taylor, S.C. Bell, Prostaglandin E(2)-dependent production of latent matrix metalloproteinase-9 in cultures of human fetal membranes, Mol. Hum. Reprod. 6 (2000) 1033-1040.
53. R.K. Sangha, J.C. Walton, C.M. Ensor, H.H. Tai, J.R. Challis, Immunohistochemical localization, messenger ribonucleic acid abundance, and activity of 15-hydroxyprostaglandin dehydrogenase in placenta and fetal membranes during term and preterm labor, J. Clin. Endocrinol. Metab. 78 (1994) 982-989.
54. C.A. Van Meir, R.K. Sangha, J.C. Walton, S.G. Matthews, M.J. Keirse, J.R. Challis, Immunoreactive 15-hydroxyprostaglandin dehydrogenase (PGDH) is reduced in fetal membranes from patients at preterm delivery in the presence of infection, Placenta 17 (1996) 291-297.
55. J.J. Kim, J. Wang, C. Bambra, S.K. Das, S.K. Dey, A.T. Fazleabas, Expression of cyclooxygenase-1 and -2 in the baboon endometrium during the menstrual cycle and pregnancy, Endocrinology 140 (1999) 2672-2678.
56. D.M. Olson, K. Skinner, J.R.G. Challis, Prostaglandin output in relation to parturition by cells dispersed from human intrauterine tissues, J. Clin. Endocrinol. Metab. 57 (1983) 694-699.
57. E.A. Willman, W.P. Collins, Distribution of prostaglandins E2 and F2 alpha within the foetoplacental unit throughout human pregnancy, J. Endocrinol. 69 (1976) 413-419.
58. K.A. Skinner, J.R. Challis, Changes in the synthesis and metabolism of prostaglandins by human fetal membranes and decidua at labor, Am. J. Obstet. Gynecol. 151 (1985) 519-523.
59. H. Khan, O. Ishihara, M.G. Elder, M.H. Sullivan, A comparison of two populations of decidual cells by immunocytochemistry and prostaglandin production, Histochemistry 96 (1991) 149-152.
60. E.R. Norwitz, P.M. Starkey, A. Lopez Bernal, A.C. Turnbull, Identification by flow cytometry of the prostaglandin-producing cell populations of term human decidua, J. Endocrinol. 131 (1991) 327-334.
61. D.M. Slater, W.J. Dennes, J.S. Campa, L. Poston, P.R. Bennett, Expression of cyclooxygenase types-1 and -2 in human myometrium throughout pregnancy, Mol. Hum. Reprod. 5 (1999) 880-884.
62. R. Romero, M. Emamian, M. Wan, R. Quintero, J.C. Hobbins, M.D. Mitchell, Prostaglandin concentrations in amniotic fluid of women with intraamniotic infection and preterm labor, Am. J. Obstet. Gynecol. 157 (1987) 1461-1467.
63. M.D. Mitchell, A.P. Flint, J. Bibby, et al., Plasma concentrations of prostaglandins during late human pregnancy: influence of normal and preterm labor, J. Clin. Endocrinol. Metab. 46 (1978) 947-951.
64. S.M. Sellers, M.D. Mitchell, J.G. Bibby, A.B. Anderson, A.C. Turnbull, A comparison of plasma prostaglandin levels in term and preterm labour, Br. J. Obstet. Gynaecol. 88 (1981) 362-366.
65. R.L. Goldenberg, J.C. Hauth, W.W. Andrews, Intrauterine infection and preterm delivery, N. Engl. J. Med. 342 (2000) 1500-1507.
66. J. McLaren, D.J. Taylor, S.C. Bell, Increased concentration of pro-matrix metalloproteinase 9 in term fetal membranes overlying the cervix before labor: implications for membrane remodeling and rupture, Am. J. Obstet. Gynecol. 182 (2000) 409-416.
67. P.H. Cherouny, G.A. Pankuch, R. Romero, et al., Neutrophil attractant/activating peptide-1/interleukin-8: association with histologic chorioamnionitis, preterm delivery, and bioactive amniotic fluid leukoattractants, Am. J. Obstet. Gynecol. 169 (1993) 1299-1303.
68. G. Rizzo, A. Capponi, D. Rinaldo, D. Tedeschi, D. Arduini, C. Romanini, Interleukin-6 concentrations in cervical secretions identify microbial invasion of the amniotic cavity in patients with preterm labor and intact membranes, Am. J. Obstet. Gynecol. 175 (1996) 812-817.
69. R. Romero, D.T. Brody, E. Oyarzun, et al., Infection and labor. III. Interleukin-1: a signal for the onset of parturition, Am. J. Obstet. Gynecol. 160 (1989) 1117-1123.
70. R. Romero, M. Mazor, Infection and preterm labor, Clin. Obstet. Gynecol. 31 (1988) 553-584.
71. A.R. Goepfert, R.L. Goldenberg, W.W. Andrews, et al., The preterm prediction study: association between cervical interleukin 6 concentration and spontaneous preterm birth. National institute of child health and human development maternal-fetal medicine units network, Am. J. Obstet. Gynecol. 184 (2001) 483-488.
72. S.R. Inglis, J. Jeremias, K. Kuno, et al., Detection of tumor necrosis factor-alpha, interleukin-6, and fetal fibronectin in the lower genital tract during pregnancy: relation to outcome, Am. J. Obstet. Gynecol. 171 (1994) 5-10.
73. S.C. Riley, C.J. Webb, R. Leask, F.M. McCaig, D.C. Howe, Involvement of matrix metalloproteinases 2 and 9, tissue inhibitor of metalloproteinases and apoptosis in tissue remodelling in the sheep placenta, J. Reprod. Fertil. 118 (2000) 19-27.
74. M.J. Willi, M. Winkler, D.-C. Fischer, T. Reineke, H. Maul, W. Rath, Chorioamnionitis: elevated interleukin-6 and interleukin-8 concentrations in the lower uterine segment, J. Perinat. Med. 30 (2002) 292-296.
75. C.L. Elliott, D.M. Slater, W. Dennes, L. Poston, P.R. Bennett, Interleukin 8 expression in human myometrium: changes in relation to labor onset and with gestational age, Am. J. Reprod. Immunol. 43 (2000) 272-277.
76. C.L. Elliott, J.A. Loudon, N. Brown, D.M. Slater, P.R. Bennett, M.H. Sullivan, IL-1beta and IL-8 in human fetal membranes: changes with gestational age, labor, and culture conditions, Am. J. Reprod. Immunol. 46 (2001) 260-267.
77. M.D. Mitchell, D.J. Dudley, S.S. Edwin, S.L. Schiller, Interleukin-6 stimulates prostaglandin production by human amnion and decidual cells, Eur. J. Pharmacol. 192 (1991) 189-191.
78. M.D. Mitchell, S.S. Edwin, S. Lundin-Schiller, R.M. Silver, D. Smotkin, M.S. Trautman, Mechanism of interleukin-1 beta stimulation of human amnion prostaglandin biosynthesis: mediation via a novel inducible cyclooxygenase, Placenta 14 (1993) 615-625.
79. M.D. Mitchell, R.J. Romero, C. Avila, J.T. Foster, S.S. Edwin, Prostaglandin production by amnion and decidual cells in response to bacterial products, Prostagl. Leukot. Essent. Fatty Acids 42 (1991) 167-169.
80. J.L. Cook, M.C. Shallow, D.B. Zaragoza, K.I. Anderson, D.M. Olson, Mouse fetal prostaglandins influence the timing of birth and uterine activation, Biol. Reprod. 68 (2003) 579-587.
81. J.L. Cook, D.B. Zaragoza, D.H. Sung, D.M. Olson, Expression of myometrial activation and stimulation genes in a mouse model of preterm labor: myometrial activation, stimulation, and preterm labor, Endocrinology 141 (2000) 1718-1728.
82. D.M. Olson, D.B. Zaragoza, M.C. Shallow, J.L. Cook, B.F. Mitchell, P. Grigsby, J. Hirst, Myometrial activation and preterm labour: evidence supporting a role for the prostaglandin F receptor, Trophoblast Res. 24 (2003) 547-554.
83. J.L. Cook, D.B. Zaragoza, N.M. White, C.L. Randall, D.M. Olson, Progesterone and prostaglandin H synthase-2 involvement in alcohol-induced preterm birth in mice, Alcohol Clin. Exp. Res. 23 (1999) 1793-1800.
84. A.R. Fuchs, F. Fuchs, Ethanol for prevention of preterm birth, Semin. Perinatol. 5 (1981) 236-251.
85. I.A. Zervoudakis, A. Krauss, F. Fuchs, Infants of mothers treated with ethanol for premature labor, Am. J. Obstet. Gynecol. 137 (1980) 713-718.
86. J.F. King, A. Grant, M.J. Keirse, I. Chalmers, Beta-mimetics in preterm labour: an overview of the randomized controlled trials, Br. J. Obstet. Gynaecol. 95 (1988) 211-222.
87. J.R. Vane, Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs, Nat. New Biol. 231 (1971) 232-235.
88. J.R. Vane, R.J. Flower, R.M. Bolting, History of aspirin and its mechanism of action, Stroke 21 (1990) IV12-IV23.
89. A.S. Kalgutkar, Z. Zhao, Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents, Curr. Drug Targets 2 (2001) 79-106.
90. F.J. Fries, Toward an understanding of NSAID-related adverse events: the contribution of longitudinal data, scard, J. Rheumatol. 25 (1996) 3-8.
91. A.L. Blower, A. Brooks, G.C. Fenn, et al., Emergency admissions for upper gastrointestinal disease and their relation to NSAID use, Aliment Pharmacol. Ther. 11 (1997) 283-291.
92. M.R. Tramer, R.A. Moore, D.J. Reynolds, H.J. McQuay, Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use, Pain 85 (2000) 169-182.
93. S.M. Cohn, S. Schloemann, T. Tessner, K. Seibert, W.F. Stenson, Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1, J. Clin. Invest. 99 (1997) 1367-1379.
94. D. Picot, P.J. Loll, R.M. Garavito, The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1, Nature 367 (1994) 243-249.
95. T.D. Warner, F. Giuliano, I. Vojnovic, A. Bukasa, J.A. Mitchell, J.R. Vane, Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis, Proc. Natl. Acad. Sci. USA 96 (1999) 7563-7568.
96. J.R. Vane, T.D. Warner, Nomenclature for COX-2 inhibitors, Lancet 356 (2000) 1373-1374.
97. R. Krishna, K.W. Riggs, E. Kwan, et al., Clearance and disposition of indometacin in chronically instrumented fetal lambs following a 3-day continuous intravenous infusion, J. Pharm. Pharmacol. 54 (2002) 801-808.
98. D.F. Anderson, T.M. Phernetton, J.H. Rankin, The measurement of placental drug clearance in near-term sheep: indomethacin, J. Pharmacol. Exp. Ther. 213 (1980) 100-104.
99. W.H. Harris, G.R. Van Petten, Placental transfer of indomethacin in the rabbit and sheep, Can. J. Physiol. Pharmacol. 59 (1981) 342-346.
100. K.J. Moise Jr., C.N. Ou, B. Kirshon, L.E. Cano, C. Rognerud, R.J. Carpenter Jr., Placental transfer of indomethacin in the human pregnancy, Am. J. Obstet. Gynecol. 162 (1990) 549-554.
101. D.W. Rurak, M.R. Wright, J.E. Axelson, Drug disposition and effects in the fetus, J. Dev. Physiol. 15 (1991) 33-44.
102. P.M. Appasamy, K. Pendino, R.R. Schmidt, K.P. Chepenik, M.B. Prystowsky, D. Goldowitz, Expression of prostaglandin G/ H synthase (cyclooxygenase) during murine fetal thymic development, Cell. Immunol. 137 (1991) 341-357.
103. M.G. Belvisi, M. Saunders, M. Yacoub, J.A. Mitchell, Expression of cyclooxygenase-2 in human airway smooth muscle is associated with profound reductions in cell growth, Br. J. Pharmacol. 125 (1998) 1102-1108.
104. H. Bamba, S. Ota, A. Kato, C. Kawamoto, K. Fujiwara, Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells, Biochem. Biophys. Res. Commun. 273 (2000) 485-491.
105. E. Castano, R. Bartrons, J. Gil, Inhibition of cyclooxygenase-2 decreases DNA synthesis induced by platelet-derived growth factor in Swiss 3T3 fibroblasts, J. Pharmacol. Exp. Ther. 293 (2000) 509-513.
106. J.A. Di Battista, S. Dore, J. Martel-Pelletier, J.P. Pelletier, Prostaglandin E2 stimulates incorporation of proline into collagenase digestible proteins in human articular chondrocytes: identification of an effector autocrine loop involving insulin-like growth factor I, Mol. Cell. Endocrinol. 123 (1996) 27-35.
107. K.A. Sorem, T.M. Siler-Khodr, Effect of IGF-I on placental thromboxane and prostacyclin release in severe intrauterine growth retardation, J. Matern. Fetal Med. 6 (1997) 341-350.
108. M. Majima, I. Hayashi, M. Muramatsu, J. Katada, S. Yamashina, M. Katori, Cyclooxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants, Br. J. Pharmacol. 130 (2000) 641-649.
109. S.C. Pearce, O.Md. Hudlicka, Effect of indomethacin on capillary growth and microvasculature in chronically stimulated rat skeletal muscles [In Process Citation], J. Physiol. 526 (Part 2) (2000) 435-443.
110. A. Nagai, M. Katayama, W.M. Thurlbeck, R. Matsui, S. Yasui, K. Konno, Effect of indomethacin on lung development in postnatal rats: possible role of prostaglandin in alveolar formation, Am. J. Physiol. 268 (1995) L56-L62.
111. J.E. Dinchuk, B.D. Car, R.J. Focht, et al., Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II, Nature 378 (1995) 406-409.
112. M. Komhoff, J.L. Wang, H.F. Cheng, et al., Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development, Kidney Int. 57 (2000) 414-422.
113. C.P. Vio, C. Balestrini, M. Recabarren, C. Cespedes, Postnatal development of cyclooxygenase-2 in the rat kidney, Immunopharmacology 44 (1999) 205-210.
114. M.Z. Zhang, J.L. Wang, H.F. Cheng, R.C. Harris, J.A. McKanna, Cyclooxygenase-2 in rat nephron development, Am. J. Physiol. 273 (1997) F994-F1002.
115. J.S. Torday, H. Sun, J. Qin, Prostaglandin E2 integrates the effects of fluid distension and glucocorticoid on lung maturation, Am. J. Physiol. 274 (1998) L106-L111.
116. K.M. Stevenson, E.R. Lumbers, Effects of indomethacin on fetal renal function, renal and umbilicoplacental blood flow and lung liquid production, J. Dev. Physiol. 17 (1992) 257-264.
117. M.E. Wlodek, S.B. Hooper, G.D. Thorburn, M.L. Tester, R. Harding, Effects of prostaglandin E2 on renal function and lung liquid dynamics in foetal sheep, Clin. Exp. Pharmacol. Physiol. 25 (1998) 805-812.
118. F. Rose, K. Zwick, H.A. Ghofrani, et al., Prostacyclin enhances stretch-induced surfactant secretion in alveolar epithelial type II cells, Am. J. Respir. Crit. Care Med. 160 (1999) 846-851.
119. W. Zaremba, E. Grunert, J.E. Aurich, Prophylaxis of respiratory distress syndrome in premature calves by administration of dexamethasone or a prostaglandin F2 alpha analogue to their dams before parturition, Am. J. Vet. Res. 58 (1997) 404-407.
120. A. Marti, M.P. Fernandez-Otero, Prostaglandin E2 accelerates enzymatic and morphological maturation of the small intestine in suckling rats, Biol. Neonate 65 (1994) 119-125.
121. T.C. Tai, S.L. Adamson, Developmental changes in respiratory, febrile, and cardiovascular responses to PGE(2) in newborn lambs, Am. J. Physiol. Regul. Integr. Comp. Physiol. 278 (2000) R1460-R1473.
122. S. Cassin, Role of prostaglandins, thromboxanes, and leukotrienes in the control of the pulmonary circulation in the fetus and newborn, Semin. Perinatol. 11 (1987) 53-63.
123. R.L. Goldenberg, R.O. Davis, R.C. Baker, Indomethacin-induced oligohydramnios, Am. J. Obstet. Gynecol. 160 (1989) 1196-1197.
124. E.M. Wintour, D. Alcorn, M.D. Rockell, Development and function of the fetal kidney, in: R.A. Brace (Ed.), Fetus and Neonate, Cambridge University Press, Cambridge, UK, 1998, pp. 3-56.
125. K.G. Peri, P. Hardy, D.Y. Li, D.R. Varma, S. Chemtob, Prostaglandin G/H synthase-2 is a major contributor of brain prostaglandins in the newborn, J. Biol. Chem. 270 (1995) 24615-24620.
126. R.I. Clyman, P. Hardy, N. Waleh, et al., Cyclooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus arteriosus, Am. J. Physiol. 276 (1999) R913-R921.
127. F. Coceani, P.M. Olley, The response of the ductus arteriosus to prostaglandins, Can. J. Physiol. Pharmacol. 51 (1973) 220-225.
128. F. Coceani, P.M. Olley, E. Bodach, Lamb ductus arteriosus: effect of prostaglandin synthesis inhibitors on the muscle tone and the response to prostaglandin E2, Prostaglandins 9 (1975) 299-308.
129. G.D. Thorburn, A time to be born, Semin. Reprod. Endocrinol. 12 (1994) 213-226.
130. C.A. Gleason, Prostaglandins and the developing kidney, Semin. Perinatol. 11 (1987) 12-21.
131. W.S. Powell, S. Solomon, Biosynthesis of prostaglandins and thromboxane B2 by fetal lung homogenates, Prostaglandins 15 (1978) 351-364.
132. M.P. Printz, R.A. Skidgel, W.F. Friedman, Studies of pulmonary prostaglandin biosynthetic and catabolic enzymes as factors in ductus arteriosus patency and closure. Evidence for a shift in products with gestational age, Pediatr. Res. 18 (1984) 19-24.
133. N. Simberg, P. Uotila, The metabolism of arachidonic acid in isolated perfused fetal and neonatal rabbit lungs, Prostaglandins 25 (1983) 629-638.
134. T.S. Brannon, A.N. MacRitchie, M.A. Jaramillo, et al., Ontogeny of cyclooxygenase-1 and cyclooxygenase-2 gene expression in ovine lung, Am. J. Physiol. 274 (1998) L66-L71.
135. T.S. Brannon, A.J. North, L.B. Wells, P.W. Shaul, Prostacyclin synthesis in ovine pulmonary artery is developmentally regulated by changes in cyclooxygenase-1 gene expression, J. Clin. Invest. 93 (1994) 2230-2235.
136. K. Asano, C.M. Lilly, J.M. Drazen, Prostaglandin G/H synthase-2 is the constitutive and dominant isoform in cultured human lung epithelial cells, Am. J. Physiol. 271 (1996) L126-L131.
137. D.M. Olson, J.E. Mijovic, D.B. Zaragoza, J.L. Cook, Prostaglandin endoperoxide H synthase type 1 and type 2 messenger ribonucleic acid in human fetal tissues throughout gestation and in the newborn infant, Am. J. Obstet. Gynecol. 184 (2001) 169-174.
138. J. Zhang, G.A. Massmann, J.P. Figueroa, Developmental and regional differences in prostaglandin-endoperoxide synthase-2 (PGHS-2) mRNA expression in fetal sheep brain. Abstract 253, J. Soc. Gynecol. Invest. 7 (2000) 115A.
139. S.G. Morham, R. Langenbach, C.D. Loftin, et al., Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse, Cell 83 (1995) 473-482.
140. R. Langenbach, S.G. Morham, H.F. Tiano, et al., Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration, Cell 83 (1995) 483-492.
141. K.J. Moise Jr., J.C. Huhta, D.S. Sharif, et al., Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus, N. Engl. J. Med. 319 (1988) 327-331.
142. M.E. Norton, J. Merrill, B.A. Cooper, J.A. Kuller, R.I. Clyman, Neonatal complications after the administration of indomethacin for preterm labor, N. Engl. J. Med. 329 (1993) 1602-1607.
143. Y. Takahashi, C. Roman, S. Chemtob, et al., Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo, Am. J. Physiol. Regul. Integr. Comp. Physiol. 278 (2000) R1496-R1505.
144. S.H. Goldbarg, Y. Takahashi, C. Cruz, et al., In utero indomethacin alters O2 delivery to the fetal ductus arteriosus: implications for postnatal patency, Am. J. Physiol. Regul. Integr. Comp. Physiol. 282 (2002) R184-R190.
145. A.R. Hohimer, B.S. Richardson, J.M. Bissonnette, C.M. Machida, The effect of indomethacin on breathing movements and cerebral blood flow and metabolism in the fetal sheep, J. Dev. Physiol. 7 (1985) 217-228.
146. J.A. Kitterman, G.C. Liggins, J.A. Clements, W.H. Tooley, Stimulation of breathing movements in fetal sheep by inhibitors of prostaglandin synthesis, J. Dev. Physiol. 1 (1979) 453-466.
147. J.A. Kitterman, G.C. Liggins, J.E. Fewell, W.H. Tooley, Inhibition of breathing movements in fetal sheep by prostaglandins, J. Appl. Physiol. 54 (1983) 687-692.
148. A.M. Rudolph, M.A. Heymann, Hemodynamic changes induced by blockers of prostaglandin synthesis in the fetal lamb in utero, in: F. Coceani, P.M. Olley (Eds.), Advances in Prostaglandin and Thromboxane Research, Raven Press, New York, 1978.
149. S.C. de Clety, M.K. Decell, M.L. Tod, P. Sirois, J.B. Gordon, Developmental changes in synthesis of and responsiveness to prostaglandins I2 and E2 in hypoxic lamb lungs, Can. J. Physiol. Pharmacol. 76 (1998) 764-771.
150. M.E. Wlodek, R. Harding, G.D. Thorburn, Effects of inhibition of prostaglandin synthesis on flow and composition of fetal urine, lung liquid, and swallowed fluid in sheep, Am. J. Obstet. Gynecol. 170 (1994) 186-195.
151. S.J. Williams, I.C. McMillen, D.B. Zaragoza, D.M. Olson, Placental restriction increases the expression of prostaglandin endoperoxide G/H synthase-2 and EP(2) mRNA in the fetal sheep kidney during late gestation, Pediatr. Res. 52 (2002) 879-885.
152. J.J. Deeks, L.A. Smith, M.D. Bradley, Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials, Br. Med. J. 325 (2002) 619.
153. M. Mamdani, P.A. Rochon, D.N. Juurlink, et al., Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclooxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs, Br. Med J. 325 (2002) 624.
154. C.J. Hawkey, Cyclooxygenase inhibition: between the devil and the deep blue sea, Gut 50 (Suppl. 3) (2002) III25-III30.
155. J.A. Oviedo, M.M. Wolfe, Clinical potential of cyclooxygenase-2 inhibitors, BioDrugs 15 (2001) 563-572.
156. T.J. Schnitzer, Cyclooxygenase-2 - specific inhibitors: are they safe? Am. J. Med. 110 (2001) 46S-49S.
157. D. Mukherjee, S.E. Nissen, E.J. Topol, Risk of cardiovascular events associated with selective COX-2 inhibitors, J. Am. Med. Assoc. 286 (2001) 954-959.
158. D. Mukherjee, S.E. Nissen, E.J. Topol, Cox-2 inhibitors and cardiovascular risk: we defend our data and suggest caution, Cleve. Clin. J. Med. 68 (2001) 963-964.
159. D.S. Sica, A.C. Schoolwerth, T.W. Gehr, Pharmacotherapy in congestive heart failure: COX-2 inhibition: a cautionary note in congestive heart failure, Congest. Heart Fail. 6 (2000) 272-276.
160. G.B. Appel, COX-2 inhibitors and the kidney, Clin. Exp. Rheumatol. 19 (2001) S37-S40.
161. R.C. Harris Jr., Cyclooxygenase-2 inhibition and renal physiology, Am. J. Cardiol. 89 (2002) 10D-17D.
162. S.R. Ahmad, C. Kortepeter, A. Brinker, M. Chen, J. Beitz, Renal failure associated with the use of celecoxib and rofecoxib, Drug Saf. 25 (2002) 537-544.
163. D.C. Brater, Renal effects of cyclooxygyenase-2-selective inhibitors, J. Pain Symptom Manage. 23 (2002) S15-S20 (discussion S21-S13).
164. H. Zuckerman, E. Shalev, G. Gilad, E. Katzuni, Further study of the inhibition of premature labor by indomethacin Part I, J. Perinat. Med. 12 (1984) 19-23.
165. J.R. Niebyl, D.A. Blake, R.D. White, et al., The inhibition of premature labor with indomethacin, Am. J. Obstet. Gynecol. 136 (1980) 1014-1019.
166. K.R. Panter, M.E. Hannah, K.S. Amankwah, A. Ohlsson, A.L. Jefferies, D. Farine, The effect of indomethacin tocolysis in preterm labour on perinatal outcome: a randomised placebo-controlled trial, Br. J. Obstet. Gynaecol. 106 (1999) 467-473.
167. R.E. Besinger, J.R. Niebyl, W.G. Keyes, T.R. Johnson, Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor, Am. J. Obstet. Gynecol. 164 (1991) 981-986 (discussion 986-988).
168. B. Kirshon, K.J. Moise Jr., G. Mari, R. Willis, Long-term indomethacin therapy decreases fetal urine output and results in oligohydramnios, Am. J. Perinatol. 8 (1991) 86-88.
169. M. Eronen, E. Pesonen, T. Kurki, O. Ylikorkala, M. Hallman, The effects of indomethacin and a beta-sympathomimetic agent on the fetal ductus arteriosus during treatment of premature labor: a randomized double-blind study, Am. J. Obstet. Gynecol. 164 (1991) 141-146.
170. D. Barker, Fetal programming of coronary heart disease, Trends Endocrinol. Metab. 13 (2002) 364.
171. R. Sawdy, D. Slater, N. Fisk, D.K. Edmonds, P. Bennett, Use of a
172. A.M. Guerguerian, P. Hardy, M. Bhattacharya, et al., Expression of cyclooxygenases in ductus arteriosus of fetal and newborn pigs, Am. J. Obstet. Gynecol. 179 (1998) 1618-1626.
173. C.S. Stika, G.A. Gross, G. Leguizamon, et al., A prospective randomized safety trial of celecoxib for treatment of preterm labor, Am. J. Obstet. Gynecol. 187 (2002) 653-660.
174. L. Peruzzi, B. Gianoglio, M.G. Porcellini, R. Coppo, Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-1 selective inhibitor nimesulide as tocolytic, Lancet 354 (1999) 1615.
175. R.P. Holmes, P.R. Stone, Severe oligohydramnios induced by cyclooxygenase-2 inhibitor nimesulide, Obstet. Gynecol. 96 (2000) 810-811.
176. A. Locatelli, P. Vergani, P. Bellini, N. Strobelt, A. Ghidini, Can a cyclooxygenase type-2 selective tocolytic agent avoid the fetal side effects of indomethacin? Bjog 108 (2001) 325-326.
177. D.B. Cotton, H.T. Strassner, L.M. Hill, B.S. Schifrin, R.H. Paul, Comparison of magnesium sulfate, terbutaline and a placebo for inhibition of preterm labor. A randomized study, J. Reprod. Med. 29 (1984) 92-97.
178. S.M. Cox, M.L. Sherman, K.J. Leveno, Randomized investigation of magnesium sulfate for prevention of preterm birth, Am. J. Obstet. Gynecol. 163 (1990) 767-772.
179. G.A. Macones, H.M. Sehdev, M. Berlin, M.A. Morgan, J.A. Berlin, Evidence for magnesium sulfate as a tocolytic agent, Obstet. Gynecol. Surv. 52 (1997) 652-658.
180. K.B. Nelson, J.K. Grether, Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 95 (1995) 263-269.
181. R. Mittendorf, R. Covert, J. Boman, B. Khoshnood, K.S. Lee, M. Siegler, Is tocolytic magnesium sulphate associated with increased total paediatric mortality? Lancet 350 (1997) 1517-1518.
182. J. Grether, D. Hirtz, D. McNellis, K. Nelson, D.J. Rouse, Tocolytic magnesium sulphate and paediatric mortality, Lancet 351 (1998) 292 (discussion 293).
183. M.T.C. Group, Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial, Lancet 359 (2002) 1877-1890.
184. J.F. King, V.J. Flenady, D.N. Papatsonis, G.A. Dekker, B. Carbonne, Calcium channel blockers for inhibiting preterm labour, Cochrane Database System Rev., 2002, CD002255.
185. R.K. Riemer, C. Buscher, R.K. Bansal, S.M. Black, Y. He, E.S. Natuzzi, Increased expression of nitric oxide synthase in the myometrium of the pregnant rat uterus, Am. J. Physiol. 272 (1997) E1008-E1015.
186. R.K. Bansal, P.C. Goldsmith, Y. He, C.J. Zaloudek, J.L. Ecker, R.K. Riemer, A decline in myometrial nitric oxide synthase expression is associated with labor and delivery, J. Clin. Invest. 99 (1997) 2502-2508.
187. I.L. Buxton, R.A. Kaiser, N.A. Malmquist, S. Tichenor, NO-induced relaxation of labouring and non-labouring human myometrium is not mediated by cyclic GMP, Br. J. Pharmacol. 134 (2001) 206-214.
188. K.K. Bradley, I.L. Buxton, J.E. Barber, T. McGaw, M.E. Bradley, Nitric oxide relaxes human myometrium by a cGMP-independent mechanism, Am. J. Physiol. 275 (1998) C1668-C1673.
189. G.N. Smith, M.C. Walker, M.J. McGrath, Randomised, double-blind, placebo controlled pilot study assessing nitroglycerin as a tocolytic, Br. J. Obstet. Gynaecol. 106 (1999) 736-739.
190. C.S. Buhimschi, I.A. Buhimschi, A.M. Malinow, C.P. Weiner, Effects of sublingual nitroglycerin on human uterine contractility during the active phase of labor, Am. J. Obstet. Gynecol. 187 (2002) 235-238.
191. M. Manning, K. Miteva, S. Pancheva, S. Stoev, N.C. Wo, W.Y. Chan, Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with atosiban, Int. J. Pept. Protein Res. 46 (1995) 244-252.
192. M.E. Miller, S.T. Davidge, B.F. Mitchell, Oxytocin does not directly affect vascular tone in vessels from nonpregnant and pregnant rats, Am. J. Physiol. Heart Circ. Physiol. 282 (2002) H1223-H1228.
193. M. Manning, S. Stoev, L.L. Cheng, N.C. Wo, W.Y. Chan, Design of oxytocin antagonists, which are more selective than atosiban, J. Pept. Sci. 7 (2001) 449-465.
194. The Worldwide Atosiban versus Beta-agonists Study Group, Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour, Bjog 108 (2001) 133-142.
195. R. Romero, B.M. Sibai, L. Sanchez-Ramos, et al., An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue, Am. J. Obstet. Gynecol. 182 (2000) 1173-1183.
196. P. Crowley, Prophylactic corticosteroids for preterm birth, Cochrane Database System Rev., 2000, CD000065.
197. H.H. Kay, I.M. Bird, C.L. Coe, D.J. Dudley, Antenatal steroid treatment and adverse fetal effects: what is the evidence? J. Soc. Gynecol. Invest. 7 (2000) 269-278.
198. N.P. French, R. Hagan, S.F. Evans, M. Godfrey, J.P. Newnham, Repeated antenatal corticosteroids: size at birth and subsequent development, Am. J. Obstet. Gynecol. 180 (1999) 114-121.
199. D.A. Guinn, M.W. Atkinson, L. Sullivan, et al., Single vs. weekly courses of antenatal corticosteroids for women at risk of preterm delivery: a randomized controlled trial, J Am. Med. Assoc. 286 (2001) 1581-1587.
200. A.H. Jobe, B.R. Mitchell, J.H. Gunkel, Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants, Am. J. Obstet. Gynecol. 168 (1993) 508-513.
201. R.K. Silver, C. Vyskocil, S.L. Solomon, A. Ragin, M.G. Neerhof, E.E. Farrell, Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered before 30 weeks' gestation, Obstet. Gynecol. 87 (1996) 683-691.
202. K.G. Allen, M.A. Harris, The role of n-3 fatty acids in gestation and parturition, Exp. Biol. Med. (Maywood) 226 (2001) 498-506.
203. J.A. McGregor, K.G. Allen, M.A. Harris, et al., The omega-3 story: nutritional prevention of preterm birth and other adverse pregnancy outcomes, Obstet. Gynecol. Surv. 56 (2001) S1-S13.
204. S.F. Olsen, H.S. Hansen, T.I. Sorensen, et al., Intake of marine fat, rich in (n-3)-polyunsaturated fatty acids, may increase birthweight by prolonging gestation, Lancet 2 (1986) 367-369.
205. S.F. Olsen, J.D. Sorensen, N.J. Secher, et al., Randomised controlled trial of effect of fish-oil supplementation on pregnancy duration, Lancet 339 (1992) 1003-1007.
206. S.F. Olsen, N.J. Secher, A. Tabor, T. Weber, J.J. Walker, C. Gluud, Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team, Bjog 107 (2000) 382-395.
207. J.E. Mijovic, T. Zakar, D.B. Zaragoza, D.M. Olson, Tyrphostins inhibit lipopolysaccharide induced preterm labor in mice, J. Perinat. Med. 30 (2002) 297-300.
208. T. Zakar, J.E. Mijovic, K.M. Eyster, D. Bhardwaj, D.M. Olson, Regulation of prostaglandin H2 synthase-2 expression in primary human amnion cells by tyrosine kinase dependent mechanisms, Biochim. Biophys. Acta 1391 (1998) 37-51.
209. T. Zakar, J.E. Mijovic, D. Bhardwaj, D.M. Olson, Tyrosine kinase inhibitors block the glucocorticoid stimulation of prostaglandin endoperoxide H synthase expression in amnion cells, Can. J. Physiol. Pharmacol. 77 (1999) 138-142.
210. C. Quiniou, K. Peri, X. Hou, D. Abran, S. Chemtob, PHG113 is a selective PGF2α receptor antagonist which delays preterm labor, J. Soc. Gynecol. Invest. 8 (2001) 79A.